REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Clinical trial NCT05870748 · TERMINATED

Trial details

NCT number: NCT05870748
Sponsor: Sutro Biopharma, Inc.
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Ovarian Cancer Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Platinum-resistant Ovarian Cancer

Start date: 2023-07-12
Primary completion: 2025-08-26
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.